Michael Schenk

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.6K citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2023 · 195 citations

Medicine, Oncology, Perioperative Medicine +17

Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study

Stephan Eddicks, K. Maier-Hauff, Michael Schenk et al. · Heart · 2007 · 167 citations · Full text

Medicine, Cardiology, Cardiothoracic Surgery +12

Familial Risk of Pancreatic Cancer

Michael Schenk, Ann G. Schwartz, Eryn Nicole O’Neal et al. · JNCI Journal of the National Cancer Institute · 2001 · 158 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15